Add
OPXA to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| OPXA > SEC Filings for OPXA > Form 8-K on 14-Nov-2012 | All Recent SEC Filings |
14-Nov-2012
Regulation FD Disclosure, Financial Statements and Exhibits
On November 14, 2012, Opexa Therapeutics, Inc. (the "Company") will deliver a corporate presentation at the Lazard Capital Markets 9th Annual Healthcare Conference, which will be available via webcast, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. The presentation includes an overview of the Company's ongoing Abili-T clinical study for Tcelna™, the Company's lead therapy, in subjects with secondary progressive multiple sclerosis. The attached materials will be made available on the Investor Relations page of the Company's website at www.opexatherapeutics.com. The Company does not undertake to update this presentation.
(d) Exhibits
Exhibit No. Description
99.1 Opexa Therapeutics, Inc. Corporate Presentation for Lazard Capital Markets 9th Annual Healthcare Conference, held on November 14, 2012.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
|
|